司美格鲁肽：以科学之名，发挥减重疗效

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, effectively aids in weight loss by enhancing insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and increasing satiety, leading to reduced appetite and food intake [2][5][8] Mechanism of Action - Semaglutide activates specific neurons in the hypothalamus, sending signals that induce a feeling of fullness before eating, which is particularly effective in treating obesity [4] - The drug reduces appetite through three main mechanisms: central action on the hypothalamus, gastrointestinal effects that slow gastric emptying, and altering food preferences, particularly reducing the intake of high-fat and sugary foods [5][7][8] Clinical Efficacy - Clinical trials show that obese patients using semaglutide for 68 weeks experienced an average weight loss of 15.3 kg, compared to 2.6 kg in the placebo group, with a weight reduction rate of 14.9% versus 2.4% [2] - Semaglutide also improves cardiovascular risk factors such as blood lipids and blood pressure, providing metabolic benefits to patients [2] Regulatory Approvals - In January 2024, Novo Nordisk's oral semaglutide, Rybelsus, was approved for the treatment of type 2 diabetes in China, marking the first oral GLP-1 receptor agonist approved in the country [9] - On June 25, 2024, the National Medical Products Administration (NMPA) approved Novo Nordisk's semaglutide injection, Wegovy, for long-term weight management in China, expanding treatment options for overweight and obese patients [11][13]